Senior editor Fay Lin interviews Geulah Livshits,senior research analyst at Chardan,. She asks him to assess the advances and challenges facing the cell therapy field.
/PRNewswire/ Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced.
Etrasimod was effective and well tolerated as an induction and maintenance therapy
in patients with moderately to severely active ulcerative colitis. Etrasimod is a
treatment option with a unique combination of attributes that might address the persistent
unmet needs of patients with ulcerative colitis.
Operator: Good morning and welcome to Editas Medicine s Fourth Quarter and Full-year 2022 Conference Call. All participants are now in a listen-only mode.